China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
China Resources Double-Crane Pharmaceutical Co., a subsidiary of China Resources Pharmaceutical Group, reported a slight increase in revenue and net profit for the nine months ending September 2024, despite a decrease in cash and cash equivalents. The company’s total assets decreased, while liabilities saw an increase, prompting cautious optimism for investors. These unaudited financial results highlight the company’s ongoing financial challenges amid a competitive market.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
